

## **CURRICULUM VITAE**

**Gustavo Alva, M.D., DFAPA**  
**Distinguished Fellow of the American Psychiatric Association**  
**Diplomate, American Board of Psychiatry and Neurology**  
**Diplomate, American Board of Geriatrics**  
**Medical Director, ATP Clinical Research**  
**3151 Airway Avenue, Suite T-3**  
**Costa Mesa, Ca. 92626**

**Telephone:** 714-277-4472  
**Fax:** 714-545-5748  
**e-mail:** galva@theatpgroup.net

**Telephone:** (949) 424-3423  
**Fax:** 714-545-5748

### **EDUCATION**

<b>Chief Resident</b>	<b>1997–1998 Department of Psychiatry and Human Behavior, UCIMC, Orange, CA. 92868</b>
<b>Residency</b>	<b>1994-1998 – Department of Psychiatry and Human Behavior, UCIMC, Orange, CA. 92868</b>
<b>Medical School</b>	<b>1986-1990 – U.A.G. – M.D. Physician/Surgeon</b>
<b>Undergraduate</b>	<b>1984-1986 – U.A.M. – Biological Sciences</b>
<b>Languages</b>	<b>English, Spanish and French</b>

<b><u>MEDICAL LICENSURE</u></b>	<b>California Licensure #A055247 Mexican Licensure #CPM 1805430</b>
---------------------------------	---

<b><u>BOARD CERTIFICATION</u></b>	<b>Diplomate, American Board of Psychiatry and Neurology Diplomate, American Board of Geriatrics Fellow of the American College of Geriatrics Specialists Diplomate of the American College of Ethical Physicians</b>
-----------------------------------	---

### **ACADEMIC APPOINTMENTS**

**2015-Present – Volunteer Faculty, University of California Riverside (UCR), Department of Psychiatry, (Clinical Assistant Professor)**  
**2010- Present –Volunteer Faculty, Midwestern University Arizona College of Osteopathic Medicine, (Clinical Assistant Professor)**

2004 – 2006- - Associate Professor, Department of Psychiatry, UCIMC  
1996 – 2004 - Assistant Professor, Department of Psychiatry, UCIMC  
1998 – 2004 - Institutional Review Board UCIMC  
1999 – 2003 - Pharmacy and Therapeutics Committee, UCIMC  
1999 - Present -Visiting Professor in Psychiatry International Program of the U.A.G. School of Medicine (Mexico)

#### **NON-ACADEMIC APPOINTMENTS**

1996-1998 - Staff Psychiatrist, Pacifica Hospital; Geriatric Psychiatrist Huntington Beach, CA  
1996-1998 - Private Practice Psychiatrist, Advantage Neuropsychiatric Associates Huntington Beach and Santa Ana, CA  
1996-1998 – Utilization/Clinical Reviewer, Newport Bay Hospital Newport Beach, CA  
1997-1998 – Chief Resident, UCI, Department of Psychiatry and Human Behavior  
1997 – Present - Forensic Psychiatric Consultant, Orange County Superior Court  
1998 – 2000- Director, Adult Acute Inpatient Service Chief, Geriatric Clinical Research Unit  
1997-1998 - Forensic Psychiatric Consultant, UCI Medical Center, Orange, CA  
1997-1998 - Staff Psychiatrist, Charter Hospital; Adult, Geriatric and Children Services Mission Viejo, CA  
2000-2002 – President Elect of the Orange County Psychiatric Society  
Quality Assurance/Utilization Review Committee, UCI, Department of Psychiatry  
Administrative/Interdisciplinary Council, UCI, Department of Psychiatry  
Medicare Compliance Committee, UCI, Department of Psychiatry  
2001-2002 – Medical Director, Acute Inpatient Unit, UCI, Department of Psychiatry and Human Behavior  
Medical Director, Schizophrenia and Bipolar Outpatient Clinic, UCI, Department of Psychiatry and Human Behavior  
2002 –2004 -President of the Orange County Psychiatric Society  
2004-Present – Immediate Past President of the Orange County Psychiatric Society  
2004-2005 – Mind Body and Harbor Medical Associates, Private Practice Psychiatrist  
2005-Present – Pacific Neuropsychiatric Specialists, Private Practice Psychiatrist  
2005-Present – Medical Director, ATP Clinical Research

#### **PROFESSIONAL ACTIVITY**

##### **Awards and Honors:**

Physicians Recognition Award by the American Medical Association, 2000-2013  
Orange Coast Magazine's Top Doctor in Psychiatry 2010 and 2011 and 2013  
Recipient of the first annual Senior Care humanitarian Award as SCHA Outstanding Physician in Dementia Care 2011

From 1996 to 2005 worked with Steven G. Potkin, M.D. at UCIMC within the Clinical Research Division of the Psychiatric department as a co-investigator and Deputy Director of the division. Participating in multiple NIH grant funded studies and multiple pharmaceutical industry grant funded studies ranging in amount from 140,000 to 999,945, and including:

- A Double Blind, Randomized, Comparison of the Safety and Efficacy of Sertindole and Risperidone in Treatment Resistant Schizophrenic Patients.
- A Double Blind, Parallel Group Study of the Efficacy and Safety of Sandoz MAR 327, as compared to Haloperidol & Placebo for the Treatment of Schizophrenia.
- A Randomized Double Blind, Placebo and Active Controlled Study of MDL 100,907 in

Schizophrenic and Schizoaffective Patients.

- A Study of the Efficacy of Risperidone, Haloperidol and Clozapine in Treatment Resistant Schizophrenic Subjects.
- A Double Blind, Placebo-Controlled, Titration Study with Sublingual Organon 5222 to Establish the Maximum Tolerated Dose in Subjects with Schizophrenia or Schizoaffective Disorders.
- A Study of the Safety and Tolerability of Escalating Doses of Mazapertine in Geriatric Schizophrenic and Schizoaffective Patients.
- A Study of the Tolerability and Safety of Either Adding Seroquel to, or Switching from, a Haloperidol Decanoate Regimen in Subjects with Selected Psychotic Disorders.
- A Study of the Safety, Efficacy and Brain Metabolic Effects of Sertindole and Risperidone in Schizophrenic and Schizoaffective Patients - PET Scan.
- The Study of the Safety, Efficacy and Brain Metabolic Effects of Olanzapine Compared to Clozapine when Administered to Schizophrenic and Schizoaffective Patients - PET Scan.
- A Double-blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder.
- Galantamine in the Treatment of Alzheimer ' s Disease: Flexible Dose Range Trial.
- A Multi-Center, Randomized, Double-blind, Active-Controlled Study to Compare the Long-Term Maintenance Effects and Safety of Aripiprazole and Haloperidol following Acute Relapse in Schizophrenic Patients.
- An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients with Chronic Schizophrenia.
- A Pilot Safety Trial to Determine the Highest Tolerable Starting Dose of Sustained-release Quetiapine Fumarate (Seroquel).
- A Prospective, Randomized, International, Parallel-Group Comparison of Clozaril/Leponex vs. Zyprexa in the Reduction of Suicide/Suicide Attempts in Patients with Schizophrenia or Schizoaffective Disorder at risk for Suicide.
- A Multicenter, Placebo and Active Control, Double -blind Randomized Study of the Efficacy, Safety, and Pharmacokinetics of M100907 in Schizophrenic and Schizoaffective Patients.
- A Double-Blind, Placebo-Controlled, Haloperidol-Referenced Study of the Safety and Efficacy of Three Doses of Iloperidone Administered to Schizophrenic Patients for 42 days.
- A 156-Week, Open Extension Study Evaluating the Safety and Outcome of 40-200 mg Daily (divided into two doses) of Oral Ziprasidone or 1-8 mg BID of Oral Risperidone Daily in the Treatment of Subjects Who Have Participated in Previous Ziprasidone Clinical Trials.
- Open Label, Parallel, Multicenter Study to Assess the Effect of Ziprasidone, Risperidone (Risperdal), Olanzapine (Zyprexa), Quetiapine (Seroquel), Thioridazine (Mellaril), and Haloperidol (Haldol) on the QTc Interval in the Absence and Presence of a Metabolic Inhibitor.
- A Prospective, Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Iloperidone (4,8, and 12 mg/day) Given bid for 42 Days to Schizophrenic Patients with Acute or Subacute Exacerbations, Followed by a Double-Blind, Active-Controlled, Flexible-Dose, Long Term, 6-Month Phase with Iloperidone (4,8,12 or 16 mg/day) Given q/day.
- A Phase II, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of Oral OPC-14523 and Prozac in the Treatment of Outpatients with Moderate Depression.
- Olanzapine versus Divalproex in the Treatment of Acute Mania.
- A Phase III Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment with Oral Ziprasidone in Subjects with Mania.
- An Open Label Study to Evaluate the Safety and Efficacy of 1.5 mgs bid (3 mg/day) through 6 mgs bid (12 mgs/day) of Exelon in Patients with mild to Severe Probable Alzheimer ' s Disease in the Community Setting.
- An Open Label Sequential Cohort Study of SDZ ENA 713 Designed to Prospectively Evaluate the Tolerability and Safety of Titrating Doses at Weekly Increases of 3 mg/day and 4 mg/day to a Maximal Dose of 12 mg/day of SDZ ENA 713 Inpatients with Probable Alzheimer ' s Disease.
- A Double Blind, Placebo-Controlled, Parallel Group, Maximum Tolerated Dose Study of Escalating Dose Ranges of NDD in Three Sequential Cohorts of Patients with Mild to Moderate Severity of Alzheimer ' s Disease.
- Genetic Factors in Neuropsychiatric Diagnosis and Treatment Response

- Surveys of Opinions Regarding the Treatment of Severe Psychiatric Illness
- An Open-Label, Six-Month Extension of SDZ ENA 713 Studies B303 (US Centers Only), B351 and B352 to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of 1 through 6 mg BID (2-12 mg/day) SDZ ENA 713 in Outpatients with Probable Alzheimer ' s Disease.
- A Prospective, Randomized, Double-Blind, Placebo-and Active Controlled, Multicenter Study to Evaluate-the Efficacy and safety of three fixed doses of Iloperidone (4, 8, and 12 mg/day) Given b.i.d. for 42 Days to Schizophrenic patients with acute or subacute exacerbations, Followed by a Double-Blind, Active-Controlled, Flexible-Dose, Long-Term, 6-Month Phase with Iloperidone (4, 8, 12 or 16 mg/day) Given q/day.
- A phase II, Randomized, Double-blind, Placebo-controlled study in the treatment of outpatients with moderate Depression
- Treating the negative symptoms of schizophrenic patients with Rapid transcranial magnetic stimulation (Rtms) of the dorsolateral prefrontal cortex.
- Brain effects of AIT-082 compared to placebo in patients with moderate to severe Alzheimer ' s Dementia.
- A Single-Center, Randomized, Double-Blind, Placebo-Controlled Titration Study with Sublingual Org 5222 to Establish the Maximum Tolerated Dose Up to a Dose of 2400 mcg Twice Daily in Subjects with Schizophrenia or Schizoaffective Disorder.
- A 260-week (5 year), Open Extension Study Evaluating the Safety and Outcome of 40-200 mg Daily of Oral Ziprasidone or 1-8 mgs BID Oral Risperidone Daily in the Treatment of Subjects Who Have Participated in Previous Ziprasidone Clinical Trials.
- A Double Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR 141716 in Schizophrenic Patients.
- A Double Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR 142801 in Schizophrenic Patients.
- A Randomized, Double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer ' s types
- A long-term extension study evaluating the safety and tolerability of BID and QD administration of memantine in patients with mild to moderate Alzheimer ' s disease
- A 52-week, prospective, randomized, double-blind, multi-center, study of relapse following transition from oral antipsychotic medication to two different doses (25 or 50 mg given every two weeks) of risperidone long-acting microspheres (Risperdal Consta) in adults with schizophrenia or schizoaffective disorder
- A 12 week, prospective, double blind, placebo controlled, multicenter study evaluating the efficacy and safety of Exelon 3-6 mgs/day in patients with Traumatic Brain Injury (TBI) with persistent cognitive deficits
- A double blind, placebo controlled, dose finding study evaluating the safety and efficacy of MKC-231, 80 mgs bid, and 20 and 80 mgs/day in the treatment of mild to moderate Alzheimer ' s disease
- A randomized, double blind, placebo controlled evaluation of the safety and efficacy of Neramexane in patients with moderate to severe dementia of the Alzheimer ' s type currently taking a Cholinesterase inhibitor
- A randomized, double blind, placebo controlled evaluation of the safety and efficacy of Neramexane in patients with moderate to severe dementia of the Alzheimer ' s type

#### **Grants and Research Awards as Principal Investigator, Predominantly 2006-Present:**

**A Placebo Controlled Study of Pregabalin and Paroxetine in Patients with Panic Disorder  
Funded by Warner Lambert– Gus Alva, M.D. Principal Investigator 11/01/00-10/31/01**

**A Placebo Controlled Study of Pregabalin in Elderly Patients with Generalized Anxiety Disorder  
Funded by Warner Lambert– Gus Alva, M.D. Principal Investigator 10/27/00-10/26/01**

**A Phase III, Randomized, Double-Blind, Placebo-Controlled, Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features (Protocol C-1073-02)**

**Funded by Corcept– Gus Alva, M.D. Principal Investigator 11/1/01-10/31/02**

**A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features Who Are Not Receiving Antidepressants or Antipsychotics (Protocol C-1073-03)**

**Funded by Corcept– Gus Alva, M.D. Principal Investigator 11/1/01-10/31/02**

**Efficacy of C-1073 (Mifepristone) in Patients With Major Depressive Disorder With Psychotic Features Who Have Previously Demonstrated a Rapid Response to Either C-1073-02 or C-1073-03**

**Funded by Corcept– Gus Alva, M.D. Principal Investigator**

**Noradrenergic Assessment of Memory Capacity**

**Investigator Initiated Protocol – Gus Alva, M.D. Principal Investigator**

**A fixed-dose, open-label, single-center, investigator initiated pilot study of the safety and efficacy of Venlafaxine as adjunct therapy to cholinesterase inhibitors on the improvement of cognitive function in non-depressed patients with Alzheimer's dementia**

**Investigator Initiated Protocol – Gus Alva, M.D. Principal Investigator**

**A Prospective, 26-week, single-arm, open-label, multi-center, pilot study evaluating the efficacy and safety of Exelon 3 to 12 mgs/day in patients with mixed dementia**

**Funded by Novartis – Gus Alva, M.D. Principal Investigator**

**A double-blind, placebo-controlled trial of the safety and efficacy of C-1073 (Mifepristone) as adjunctive therapy in Alzheimer's disease.**

**Funded by Corcept – Gus Alva, M.D. Principal Investigator**

**A prospective, randomized, parallel-cohort, multicenter, 13-week, open-label comparative study of the effects of Exelon® (rivastigmine tartrate) 6 to 12 mg/day, Aricept® (donepezil HCl) 5 to 10 mg/day and Reminyl® (galantamine bromide) 16 to 24 mg/day on CSF cholinesterase activity in patients with mild to moderate Alzheimer's disease**

**Funded by**

**Novartis – Gus Alva, M.D. Principal Investigator**

**A Multicenter, Randomized, Parallel-group, Double-blind, Phase III**

**Comparison of the Efficacy and Safety of Quetiapine Fumarate**

**(oral tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance**

**Treatment of Bipolar I Disorder in Adult Patients**

**Funded by Astra Zeneca – Gus Alva, M.D. Principal Investigator**

**A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features Who Are Receiving Escitalopram (Protocol C-1073-06)**

**Funded by Corcept– Gus Alva, M.D. Principal Investigator**

**A Phase II, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease**

**Funded by Corcept– Gus Alva, M.D. Principal Investigator**

**A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety,**

**Tolerability, and Efficacy Study of 3 doses of Lecozotan (SRA-333) In Outpatients with Mild to Moderate Alzheimer's Disease Treated with a Cholinesterase Inhibitor**  
Funded by Wyeth-Gus Alva, M.D. Principal Investigator

**A Multicenter, Randomized, Double-blind, Long-term Extension Study To Determine The Safety, Tolerability, And Preliminary Long Term Efficacy Of Lecozotan (SRA-333) SR In Patients With Mild To Moderate Alzheimer's Disease**  
Funded by Wyeth – Gus Alva, Principal Investigator

**A Multicenter, Randomized, Double-blind, Long-term Extension Study To Determine The Safety, Tolerability, And Preliminary Long Term Efficacy Of Lecozotan (SRA-333) SR In Patients With Mild To Moderate Alzheimer's Disease Treated with a Cholinesterase Inhibitor**  
Funded by Wyeth – Gus Alva, Principal Investigator

**An Open-label Extension Study To Evaluate The Long-term Safety And Tolerability Of Bifeprunox In The Treatment Of Outpatients With Schizophrenia**  
Funded by Wyeth – Gus Alva, Principal Investigator

**Phase 3 Multi Center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type**  
Funded by Myriad – Gus Alva, M.D. Principal Investigator

**A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer's Type (MEM-MD-50)**  
Funded by Forest – Gus Alva, Principal Investigator

**MEM-MD-54: An Open-Labeled Extension Study Evaluating the Safety and Tolerability of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer's type.**  
Funded by Forest – Gus Alva, Principal Investigator

**An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1 mg sublingual tablets administered once daily in patients with Major Depressive Disorder (Protocol CAGO178C2302)**  
Funded by Novartis - Gus Alva, Principal Investigator

**A 52-week, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the long-term efficacy, tolerability and safety of agomelatine 25 and 50 mg in the prevention of relapse of Major Depressive Disorder (MDD) following open-label treatment of 16-24 weeks**  
Funded by Novartis – Gus Alva, Principal Investigator

**A multicenter, randomized, double-blind, fixed-dose, efficacy and safety trial of farampator (Org 24448) (250 and 500 mg b.i.d.) vs. placebo as augmentation therapy in schizophrenic subjects currently receiving risperidone (2 or 3 mg b.i.d.)**  
Funded by Organon – Gus Alva, Principal Investigator

**Protocol 01-05-TL-375-061: A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Community Dwelling, Mild to Moderately Severe Alzheimer's Disease Subjects.**  
Funded by Takeda – Gus Alva, Principal Investigator

**A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder**

**Funded by Janssen – Gus Alva, Principal Investigator**

**Trial A1281137: A Phase 3, Randomized, 6-Month, Double Blind Trial In Subjects With Bipolar I Disorder To Evaluate The Continued Safety And Maintenance Of Effect Of Ziprasidone Plus A Mood Stabilizer (Vs Placebo Plus A Mood Stabilizer) Following A Minimum Of 2 Months Of Response To Open-label Treatment With Both Agents**

**Funded by Pfizer – Gus Alva, Principal Investigator**

**A Sixteen-Week, Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of switching from Quetiapine to Ziprasidone in Subjects Diagnosed with Schizophrenia or Schizoaffective Disorder**

**Funded by Pfizer – Gus Alva, Principal Investigator**

**Randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of Major Depressive Disorder in elderly patients; Study 12541A**

**Sponsored by Lundbeck – Gus Alva, Principal Investigator**

**Efficacy of Aripiprazole in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy (Study No. CN138-189)**

**Funded by Bristol Myers Squibb/Otsuka– Gus Alva, M.D. Principal Investigator**

**A Multicenter, Randomized, Double-blind, Placebo-controlled, 16-Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy (Study no.CN138-397)**

**Funded by Bristol Myers Squibb/Otsuka– Gus Alva, M.D. Principal Investigator**

**Protocol SGS518-CL03: A double-blind, placebo-controlled, dose-ranging, parallel-group study in adults with cognitive impairment associated with schizophrenia (CIAS)**

**Funded by Saegis– Gus Alva, M.D. Principal Investigator**

**A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia**

**Funded by Organon - Gus Alva, Principal Investigator**

**A Randomized, Placebo Controlled, Double-Blind Phase IIb Study of AZD3480 in the Treatment of Cognitive Deficits in Patients with Schizophrenia**

**Funded by Astra-Zeneca - Gus Alva, Principal Investigator**

**Protocol A7501021, A randomized, parallel group, multiple dose, 6-week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis**

**Funded by Pfizer – Gus Alva, Principal Investigator**

**A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed Protocol A7501013**

**Funded by Pfizer – Gus Alva, Principal Investigator**

**Study MEM-MD-50 A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer's Type**

**Funded by Forest– Gus Alva, M.D. Principal Investigator**

**Protocol A7501013: “A Multicenter, Double-Blind, Flexible-Dose, 6Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia”**

**Funded by Pfizer– Gus Alva, M.D. Principal Investigator**

**A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects who Completed Protocol A7501013**

**Funded by Pfizer– Gus Alva, M.D. Principal Investigator**

**Protocol A7501021, A randomized, parallel group, multiple dose, 6-week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis**

**Funded by Pfizer– Gus Alva, M.D. Principal Investigator**

**Protocol 01—5-TL-375-061, A double-blind, Randomized, placebo-controlled study of the efficacy, Safety and tolerability of 8 week treatment of Rozerem 8 mg (QHS) in sleep disturbed, community dwelling, mild to moderately severe, Alzheimer's disease patients**

**Funded by Takeda – Gus Alva, Principal Investigator**

**A Phase II Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety In-patient Study of Staccato™ Loxapine for Inhalation in Patients with Agitation in Schizophrenia**

**Funded by Alexza – Gus Alva, MD Principal Investigator**

**An open label, parallel group, multicenter study, comparing the safety and imaging characteristics of 18F-AV-45 for brain imaging of amyloid in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD)**

**Funded by Avid Radiopharmaceuticals - Gus Alva, M.D. Principal Investigator**

**Observational study of long-term (18 month) cognitive outcomes in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimer's disease (AD) who have previously had PET imaging with florpiramine F 18 (18F-AV-45) Injection**

**Funded by Avid Radiopharmaceuticals - Gus Alva, M.D. Principal Investigator**

**Effect of LY450139, a gama-secretase inhibitor, on the Progression of Alzheimer's Disease as compared with Placebo**

**Funded by Lilly - Gus Alva, Principal Investigator**

**Effect of LY2062430, an Anti-Amyloid Beta monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared with Placebo (Study H8A-MC-LZAM)**

**Funded by Lilly - Gus Alva, Principal Investigator**

**A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia**

**Funded by Astra-Zeneca – Gus Alva, Principal Investigator**

**Protocol ELN115727-301, “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB–001,**



**ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E e4 Non-Carriers"**

**Funded by Elan – Gus Alva, Principal Investigator**

**Protocol ELN115727-302, "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E e4 Carriers"**

**Funded by Elan – Gus Alva, Principal Investigator**

**A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer's disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106 (Phase IIA)**

**Funded by Novartis – Gus Alva, Principal Investigator**

**A Study of Augmentation with LY2216684 for Patients with Major Depressive Disorder who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment", protocol H9P-MC-LNDK**

**Funded by Lilly – Gus Alva, Principal Investigator**

**A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from Donepezil to Rivastigmine Patch Formulation in Patients with Probable Alzheimer's Disease**

**Funded by Novartis – Gus Alva, Principal Investigator**

**A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety and Tolerability of Exelon® 10 and 15 cm<sup>2</sup> Patch in Patients with Alzheimer's Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase**

**Funded by Novartis – Gus Alva, Principal Investigator**

**A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm<sup>2</sup> vs. Rivastigmine Patch 5 cm<sup>2</sup> on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type**

**Funded by Novartis – Jason Kellogg, Principal Investigator**

**Effect of Gamma Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo, protocol H6L-MC-LFBC**

**Funded by Lilly – Gus Alva, Principal Investigator**

**CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease**

**Funded by Medivation – Gus Alva, Principal Investigator**

**CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil**

**Funded by Pfizer – Gus Alva, Principal Investigator**

**A Phase 3, Randomized, Double-blind, Parallel Group, 10-Week, Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder**

**Funded by Pfizer– Gus Alva, M.D. Principal Investigator**

**A Phase 2 Multicenter, Double-blind Placebo Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease  
Funded by Pfizer – Gus Alva, Principal Investigator**

**Evaluation of the Long-Term Safety, Tolerability, and pharmacokinetics of Cariprazine in Patients with Schizophrenia (RGH-MD-11)  
Funded by Forest - Gus Alva, Principal Investigator**

**A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled 26 week trial to evaluate the Efficacy and Safety of Dimebon (Latrepiridine, PF-01913539) in Patients with Moderate-to-Severe Alzheimer's Disease  
Funded by Pfizer - Gus Alva, Principal Investigator**

**A Randomized, 18-week, Placebo-Controlled, Double-Blind, Parallel Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) In Subjects with Mild-to Moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On a Stable Daily Dose Of Donepezil  
Funded by Pfizer – Gus Alva, Principal Investigator**

**A 24 -Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of 3 dosage levels of SAM-531 in Outpatients with Mild to Moderate Alzheimer's Disease Treated with a Cholinesterase Inhibitor (SAM 531-2002)  
Funded by Wyeth – Gus Alva, Principal Investigator**

**A Double-blind Placebo-controlled Preliminary Study Of The Efficacy, Safety And Tolerability Of ST101 In The Treatment Of Alzheimer's Disease  
PROTOCOL NUMBER: ST101-A001-201  
Funded by Sonexa – Gus Alva, Principal Investigator**

**A Double-blind Placebo-controlled Preliminary Study Of The Efficacy, Safety And Tolerability Of ST101 In The Treatment Of Alzheimer's Disease In Subjects Concurrently Receiving Donepezil (Aricept®) Protocol Number: ST101-A001-202  
Funded by Sonexa – Gus Alva, Principal Investigator**

**Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia Protocol RGH-MD-11  
Funded by Forest – Gus Alva, Principal Investigator**

**A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Adaptive Design Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in subjects with Mild to Moderate Probable AD  
Funded by En Vivo – Gus Alva, Principal Investigator**

**A 24 months, multi-center, randomized, double-blind, placebo-controlled, parallel group, study in patients with mild Alzheimer's Disease (AD) to investigate the safety, tolerability and A beta-specific antibody response following repeated S.C and/or IM injections of adjuvated CAD 106  
Funded by Novartis- Gus Alva, Principal Investigator**

**A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer's disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD 106**

**Funded by Novartis – Gus Alva, Principal Investigator**

**A Double-blind, Placebo-Controlled, Fixed-Dose Study of F2695 SR in Patients with Major Depressive Disorder LVM-MD-01**

**Funded by Forest – Gus Alva, Principal Investigator**

**A multinational, multicenter, randomized, double-blind, parallel-group, placebo controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy**

**Funded by Sanofi Aventis – Gus Alva, Principal Investigator**

**A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adult Patients with Major Depressive Disorder (Protocol 331-08-212)**

**Funded by Otsuka - Gus Alva, Principal Investigator**

**A 12 week, Randomized, Multicenter, Open-Label, Iloperidone, (12-24 mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine, or Aripiprazole (i-FANS)**

**Funded by Novartis - Gus Alva, Principal Investigator**

**A phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and efficacy of Two Fixed Doses of OPC-34712 as Adjunctive therapy in the Treatment of Adults with Major Depressive Disorder, The Polaris Trial (Protocol 331-10-227)**

**Funded by Otsuka - Gus Alva, Principal Investigator**

**A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion Trial (Protocol 331-10-238)**

**Funded by Otsuka - Gus Alva, Principal Investigator**

**A Multicenter, Randomized, Double-blind, Placebo-controlled, Fluoxetine-referenced, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder**

**Funded by Pfizer - Gus Alva, Principal Investigator**

**A 6-Month, Open-label, Multicenter, Flexible-dose Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder**

**Funded by Pfizer - Gus Alva, Principal Investigator**

**Protocol SHN-KAP-401: A 40-week, Phase 4, Double-blind, Placebo-controlled, Multicenter, Randomized-withdrawal Study to Evaluate the Long-term Efficacy and Safety of KAPVAY™ (clonidine hydrochloride) Extended-Release In Children and Adolescents with Attention Deficit Hyperactivity Disorder**

**Funded by Shionogi - Gus Alva, Principal Investigator**

**A Double-Blind, Placebo-and Active-Controlled, Fixed-Dose Study of Vilazodone in Patients with Major Depressive Disorder (VLZ-MD-01)**

**Funded by Forest - Gus Alva, Principal Investigator**

**A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder (VLZ-MD-02)**  
**Funded by Forest - Gus Alva, Principal Investigator**

**VLZ-MD-07 A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in the Treatment of Generalized Anxiety Disorder**  
**Funded by Forest - Gus Alva, Principal Investigator**

**A Phase 2, Randomized, Double-blind, Placebo- Controlled, Dose Titration Study to Assess the Safety and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia (Kinect 2)**  
**Funded by Neuronetics - Gus Alva, Principal Investigator**

**AC-12-010: A 26 Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26-week Open-Label Extension**  
**Funded by Accera - Gus Alva, Principal Investigator**

**A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 (for up to 2 years) on Potential Biomarkers of Neurodegeneration in Subjects with Mild Cognitive Impairment**  
**Funded by Chiesi - Gus Alva, Principal Investigator**

**A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features**  
**Funded by Corcept - Gus Alva, Principal Investigator**

**A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26 week Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40 mg, 80 mg, 100 mg) and High Dose Range (120 mg, 140 mg, 160 mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults who have Persistent Predominant Negative Symptoms of Schizophrenia**  
**Funded by Shire - Gus Alva, Principal Investigator**

**A Phase 3, Long Term, Open-label, Multicenter, 52 week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults who have Persistent Predominant Negative Symptoms of Schizophrenia**  
**Funded by Shire - Gus Alva, Principal Investigator**

**Feasibility Study: Safety and Efficacy Assessment of SAPPHIRE II System to Aid in the Diagnosis of Probable Alzheimer's disease in twenty normal subjects and twenty patients with probable Alzheimer's disease**  
**Funded by Cognoptix - Gus Alva, Principal Investigator**

**A Randomized, Double-blind, Placebo-controlled, Parallel, 26 week, phase 3 Study of 2 Doses of an Alpha-Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy**  
**Funded by En Vivo- Gus Alva, Principal Investigator**

**A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of**

**Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy  
Funded by EnVivo - Gus Alva, Principal Investigator**

**A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder  
Funded by Otsuka - Gus Alva, Principal Investigator**

**A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in subjects with Alzheimer's Disease  
Funded by Merck – Gus Alva, Principal Investigator**

**A Phase 3, 12 week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer's Type  
Funded by Otsuka – Gus Alva, Principal Investigator**

**A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect  
Funded by Avanir – Gus Alva, Principal Investigator**

**An Exploratory, Multicenter, Randomized, Double-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 AND 4 MG/DAY TABLETS) in Adults with Schizophrenia with Impulsivity  
Funded by Otsuka – Gus Alva, Principal Investigator**

**A Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; Study 2 STARBEAM(Lu AE58054; Phase III)  
Funded by Lundbeck – Gus Alva, Principal Investigator**

**A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof of Concept, Dose-Finding Study to Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild Dementia Due to Alzheimer's Disease  
Funded by Eisai – Gus Alva, Principal Investigator**

**A Multicenter, Double-blind, Placebo and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients with Major Depressive Disorder (VLZ MD 22)  
Funded by Forest – Gus Alva, Principal Investigator**

**An Open Label Long Term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder (VLZ MD 23)  
Funded by Forest – Gus Alva, Principal Investigator**

#### **Offices held in professional societies and scholarly organizations**

**2004-2006 – Immediate Past President, Orange County Psychiatric Society**

**2002-2004 – President, Orange County Psychiatric Society**

**2002-Present – Founding Member, International Congress of Geriatric Psychopharmacology**

**2000-2002 – President Elect, Orange County Psychiatric Society**

**1998 – 2006 – Council, California Psychiatric Association**

#### **Invited presentations**

- 1) Alva, G – Invited Speaker: "Atypical Antipsychotics and their effect on Mood", St. Joseph's Hospital, Grand Rounds, Dec., 10, 1999
- 2) Alva, G – Invited Speaker: "Depression Across the Lifecycle", Harbor UCLA, Family Medicine Grand Rounds, February, 3, 2000
- 3) Alva, G – Invited Speaker: "Update of Insomnia and Parasomnias", UCI, Psychiatry Grand Rounds, February, 15, 2000
- 4) Alva, G – Invited Speaker: "Differentiating normal aging from Alzheimer's Disease", Saddleback Memorial Hospital, 7<sup>th</sup> Annual Mental Health Conference, February 18, 2000
- 5) Alva, G – Invited Speaker: "Improving the management of depression", San Diego Psychiatric Mental Health Clinic, Grand Rounds, February 23, 2000
- 6) Alva, G – Invited Speaker: "Recognizing the comorbidity of affective disorders", UCI, Family Medicine, Grand Rounds, April 4, 2000
- 7) Alva, G – Invited Speaker: "New agents to treat Alzheimer's and other dementias", UCI, Family Medicine, Grand Rounds, April 12, 2000
- 8) Alva, G – Invited Speaker: "Recognizing anxiety disorders", National Anxiety Disorder Day, NAMI, Orange, May 3, 2000
- 9) Alva, G – Invited Speaker: "Improving the management of depression and anxiety disorders", Long Beach Memorial, Family Medicine Grand Rounds, May 5, 2000
- 10) Alva, G – Invited Speaker: "Major Depressive Disorder; Beyond Vegetative Symptoms", Mission Community Hospital, May 17, 2000
- 1) Alva, G – Invited Speaker: "Depression Across the Female Lifecycle", LA Co. Harbor-UCLA, Dept. of Obstetrics and Gynecology, Grand Rounds, June, 12, 2000
- 2) Alva, G – Invited Speaker: "Beyond Vegetative Symptoms of Depression; Overlapping Affective Disorders", Harbor UCLA, Family Medicine Grand Rounds, June 13, 2000
- 3) Alva, G – Invited Speaker: "Update on the treatment of Depression and Anxiety Disorders", Orange County Mental Health Meeting, July 12, 2000
- 4) Alva, G – Invited Speaker: "A volatile combination; Anxiety Disorders and Substance Abuse", NCPS CME meeting, August 3, 2000
- 5) Alva, G – Invited Speaker: "The Role of Cholinergic Therapy in the Treatment of Alzheimer's Disease and Other Dementias", Woodland Hospital, General Grand Rounds, August 9, 2000
- 6) Alva, G – Invited Speaker: "Advances in the treatment of Alzheimer's Disease", Long Beach Memorial, General Grand Rounds, August 17, 2000
- 7) Alva, G – Invited Speaker: "The rationale of current treatment strategies in slowing down Alzheimer's disease", San Joaquin Hospital, Internal Medicine Grand Rounds, August 24, 2000
- 8) Alva, G – Invited Speaker: "Advances in the Research Setting Related to Alzheimer's Disease", Lodi Memorial Hospital, Internal Medicine Grand Rounds, September 8, 2000
- 9) Alva, G – Invited Speaker: "Recognizing Suicide Risk", St. Francis Medical Center, Grand Rounds, Sept., 12, 2000
- 10) Alva, G – Invited Speaker: "Management of Alzheimer's Disease", La Jolla VA Medical Center, Psychiatry Grand Rounds, September 20, 2000
- 11) Alva, G – Invited Speaker: "Alzheimer's Disease Treatment Update", Hoag Hospital, Grand Rounds, October 3, 2000
- 12) Alva, G – Invited Speaker: "Alzheimer's Disease", Good Samaritan Hospital, Grand Rounds, Oct. 11, 2000
- 13) Alva, G – Invited Speaker: "Caring for an Aging America-Differential Diagnoses of

Dementia in the Elderly", Paradise Senior Health Center, Oct. 18, 2000

- 1) Alva, G – Invited Speaker:" "The Role of Cholinergic Therapy in the Treatment of Alzheimer's Disease", Washington Hospital Medical staff, Grand Rounds, Oct. 27, 2000
- 2) Alva, G – Invited Speaker:" "Management of Alzheimer's Disease", Torrance Memorial Medical Center, Grand Rounds, November 15, 2000
- 3) Alva, G – Invited Speaker:" "Alzheimer's Disease", Kaiser Permanente, Dept. of Neurology Grand Rounds, November 16, 2000
- 4) Alva, G – Invited Speaker:" "Affective Disorders through the Lifecycle and their impact on comorbid medical conditions", Charles Drew, Internal Med. Grand rounds, November, 21, 2000
- 5) Alva, G – Invited Speaker:" "Mood Disorders and Sleep", King Drew, Internal Medicine Grand Rounds, January 10, 2001
- 6) Alva, G – Invited Speaker:" "Dementing Disorders", St. Vincent Medical Center, Internal Medicine Grand Rounds, February 15, 2001
- 7) Alva, G – Invited Speaker:" "Alzheimer's Disease and other Dementias", Hispanic Medical Association CME Meeting, February 22, 2001
- 8) Alva, G – Invited Speaker:" "Sleep Disorders and their impact on psychiatric Disease", Drew Medical Center, Psychiatry Grand Rounds, February 27, 2001
- 9) Alva, G – Invited Speaker:" "Advances in the Treatment of Alzheimer's Disease", O'Connor Medical Center, General Grand Rounds, April 3, 2001
- 10) Alva, G – Invited Speaker:" "Update on Schizophrenia", UCI Pathology Grand Rounds, April 11, 2001
- 11) Alva, G – Invited Speaker:" "The Biological Underpinnings between Sleep Disorders and Affective Disorders", San Antonio Hospital, General Grand Rounds, May 10, 2001
- 12) Alva, G – Invited Speaker:" "Thymolepsis with Atypical Antipsychotics", Loma Linda VA Medical Center, Psychiatry Grand Rounds, June 19, 2001
- 13) Alva, G – Invited Speaker:" "Advances in the Treatment of Alzheimer's Disease", UCI, Psychiatry Grand rounds, September 4, 2001
- 14) Alva, G – Invited Speaker:" "Current advances in treating comorbid affective disorders", OC Family Medicine Association, CME talk, September 4, 2001
- 15) Alva, G – Invited Speaker:" "What changes have occurred in treating the Dementias?", Saddleback Memorial Hospital, 8<sup>th</sup> Annual Mental Health Conference, Keynote Speech, September 5, 2001
- 16) Alva, G – Invited Speaker:" "Advances in the treatment of Bipolar Disorder", OCPS CME lecture, September 5, 2001
- 17) Alva, G – Invited Speaker:" "Seeking Remission in treating Affective Disorders", Vista Community Hospital, General Grand Rounds, September 28, 2001
- 18) Alva, G – Invited Speaker:" "Research update on the comorbidity of Psychotic illness and affective disorders", Grand Rounds, Metropolitan State Hospital, October 17, 2001
- 19) Alva, G – Invited Speaker:" "Depression Across the Lifecycle", Western Medical Center, Grand Rounds, 1999
- 20) Alva, G – Invited Speaker:" "Typically Considering Atypicals for Psychosis", U.A.G., Psychiatric Department – Grand Rounds, 1999
- 21) Alva, G – Invited Speaker:" "Delirium, Dementia and the Amnestic Disorders; a clinical update", 1999, U.A.G. – Grand Rounds -"
- 22) Alva, G – Invited Speaker:" "Differences between normal aging, mild cognitive impairment and AD", 1999, Good Morning America
- 23) Alva, G – Invited Speaker:" "Psychological effects of war on people – an update of PTSD", 1999, Hispanic Radio Network (Spanish counterpart of NPR)
- 24) Alva, G – Invited Speaker:" "Psychiatric comorbidities with Major depressive Disorder", 1999, Presentation to Senator Dunn
- 25) Alva, G – Invited Speaker:" Grand Rounds – Metropolitan State Hospital, 1999"Research update on Alzheimer's Dementia"
- 26) Alva, G – Invited Speaker:" Manic Depressive Association of O.C., 1998 – "New Treatment options for Bipolar Affective disorder"
- 27) Alva, G – Invited Speaker:" Grand Rounds, UCIMC, Department of Psychiatry and Human Behavior, 1996 "ECT and other treatment augmentation strategies for refractory

Schizophrenic Patients"

- 28) Alva, G – Invited Speaker: " Grand Rounds, Metropolitan State Hospital, 2002 "Medico legal Issues in Treating The Psychotic Patient"
- 29) Alva, G – Invited Speaker: Grand Rounds, Patton State Hospital, March, 13, 2002 "Management of Aggressive Behaviors in the Elderly Medically Compromised Patient"
- 30) Alva, G – Invited Speaker: Grand Rounds, Loma Linda Family Practice Department, March 20, 2002, "Optimizing the diagnosis and treatment of Acutely Psychotic Patients in an Emergency Setting"
- 31) Alva, G – Invited Speaker: Grand Rounds, White Memorial, Family Practice Program, April 4, 2002, "Identification and optimal treatment of comorbid affective disorders in the medically compromised patient"
- 32) Alva, G – Invited Speaker: Grand Rounds, Kaiser Los Angeles Department of Psychiatry, April 15, 2002, "Advances in neuroimaging and treatment of psychotic illness"
- 33) Alva, G – Invited Speaker: Grand Rounds, Loma Linda Internal Medicine, April 26, 2002, "Forensic Issues and their nuances in psychiatric patients"
- 34) Alva, G – Invited Speaker: Grand Rounds, Loma Linda VA Internal Medicine, May 10, 2002, "Impact of affective disorders on medical comorbidities; Optimal management"
- 35) Alva, G – Invited Speaker, Grand Rounds, Metropolitan State Hospital, July 10, 2002, "Forensic Developments in the treatment of Psychotic Patients"
- 36) Alva, G – Invited Speaker: " Grand Rounds, San Francisco VA, August 2, 2002 "Optimal Management of Psychosis and Agitation in the Elderly"
- 37) Alva, G – Invited Speaker, Orange County MENSA, August 9, 2002, "Update on Dementing Illnesses"
- 38) Alva, G – Invited Speaker, Grand Rounds, Department of Psychiatry, UCI, August 27, 2002 "Clinical Research Division Update; Emphasis on Psychotic Depression"
- 39) Alva, G – Invited Speaker, CPA Annual Meeting, Co-Chair for symposium for Early Career Psychiatrists, September 21, 2002
- 40) Alva, G – Invited Speaker, Grand Rounds, Department of Psychiatry, UCI, September 24, 2002, "Stereoisomers, Advances in the treatment of affective disorders"
- 41) Alva, G – Invited Speaker, OCPS General Lecture, October 2, 2002, "Update on the diagnosis and treatment of Dementias"
- 42) Alva, G – Invited Speaker, North Colorado Medical Center, Grand Rounds, October 18, 2002, "Current Advances in the Treatment of Dementias"
- 43) Alva, G – Invited Speaker, Las Vegas VA, Grand Rounds, December 3, 2002, "Forensic Issues in dealing with Psychotic Illness"
- 44) Alva, G - Faculty, CME event; Measuring and Treating Depression: A Psychiatrist's perspective, 2002
- 45) Alva, G – Invited Speaker, Loma Linda Internal Medicine, Grand Rounds, December 19, 2002, "Addressing comorbid medical and affective disorders"
- 46) Alva, G – Invited Speaker, Loma Linda Psychiatry, Grand Rounds, January 7, 2003, "Current Advances in the Treatment of Psychotic Disorders"
- 47) Alva, G – Invited Speaker, Good Samaritan Hospital, Grand Rounds, January 17, 2003, "Novel approaches in detecting and treating negative symptom schizophrenia, a PET update"
- 48) Alva, G – Invited Speaker, Patton State Hospital, Grand Rounds, March 4, 2003, "Current Advances in the Treatment of Psychotic Disorders"
- 49) Alva, G – Invited Speaker, Tarzana Hospital, Grand Rounds, March 11, 2003, "Current Advances in the Treatment of Dementias"
- 50) Alva, G – Invited Speaker, 29 Palms Naval Hospital, Grand Rounds, April 16, 2003, "Managing Depression and Anxiety in the medically compromised patient"
- 51) Alva, G – Invited Speaker, Loma Linda Psychiatry, Grand Rounds, January 7, 2003, "Current Advances in the Treatment of Psychotic Disorders"
- 52) Alva, G – Invited Speaker, Augustus Hawkins Psychiatry Grand Rounds, October 28, 2003 "Integrating Community Psychiatry and Clinical Research Into Public Health"
- 53) Alva, G - Faculty, CME Event sponsored by CME Inc; Maximizing Outcomes in the Management of Anxiety: What Clinicians Need to Know, 2004
- 54) Alva, G - Faculty, CME Event sponsored by CME Inc; "Recognizing and Managing Agitation, Dementia and Other Behavioral Disturbances in the Nursing Home: A Multidisciplinary



Approach, 2004

- 55) Alva, G - Faculty, CME sponsored by Optima Educational Solutions, "Alzheimer's Disease: Current Challenges and Emerging Changes in Treatment Strategies, 2004
- 56) Alva, G - Invited Speaker, American Medical Directors Association 28<sup>th</sup> Annual Symposium held on March 17, 2005, "Modifying Alzheimer's Disease Progression in Long-Term Care: An Interactive Discussion (A CME/CE satellite symposium)
- 57) Alva, G - Invited Speaker, Nadona Conference, June 29, 2005, "Prolonging Function through early diagnosis and optimized management of Alzheimer's Disease" (A CE Satellite Symposium)
- 58) Alva, G - Program Chair, Improving Physical and Mental Outcomes: How Anxiety Impacts Co-morbid Conditions - A Primary Care Physicians Perspective. Series of CME lectures, 2005
- 59) Alva, G - Faculty - Impact Insomnia - Insomnia Management: Proving Advances in Care and Treatment; Jointly Sponsored by the University of Wisconsin Med school and Academic Alliances in Medical Education; CME event, 2005
- 60) Alva G - Faculty at Symposium titled, "Taking the Science to the Patient", at the American Psychiatric Association 2005 Institute on Psychiatric Services in San Diego, Ca.
- 61) Alva, G - Faculty at the 2005 U.S. Psychiatric and Mental Health Congress, Tuesday, November 8, 2005; Symposia presentation "Differentiating Psychotic Features in Bipolar Disorder From Schizophrenia: Treatment Implications"
- 62) Alva, G - Invited Speaker and Chairman of A CME Symposium, American Medical Directors Association's (AMDA) 2006 Annual Meeting, March 16, 2006, Dallas, Texas. "The Challenges in the Treatment of Anxiety and Depression in the Elderly Patient"
- 63) Alva, G - Faculty, CME Event sponsored by Intelyst Medical Communication, The Blue plate Special; Recipe for Managing Depression, 2006
- 64) Alva, G - Invited Speaker, Pri Med Psychiatry Updates 2006 program on May 12<sup>th</sup>, Los Angeles
- 65) Alva, G - Invited Speaker, the 18th Annual U.S. Psychiatry & Mental Health Congress, "Differentiating Psychotic Features in Bipolar Disorder from Schizophrenia: Treatment Implications.
- 66) Alva, G - Invited Speaker, Managed Care Advisory Board Meeting, "Understanding the Managed Care Implications on Compliance and Persistency in the Treatment of Depression", June 21, 2006, Santa Monica, Ca.
- 67) Alva, G - Faculty, CME event on Lifelong Learning Initiative of Bipolar Disorder, "Confronting the Diagnostic Challenges in Bipolar Disorder: Examining Stigma and Cultural Barriers, 2006
- 68) Alva, G and Chou, J, Invited Speaker and co-Chair, "Improving Patient Outcomes in the Management of Bipolar Disorder: Focus on Special Populations, Cultural Disparities, Efficacy and Safety", Nov. 11, Costa Mesa, Ca. A CME LLC half-day educational meeting series titled "Understanding the Complexity of Patients and Treatment in Bipolar Disorder: A Case Based Approach"
- 69) Alva, G - Invited Speaker, Optimizing Cognitive Outcomes in Alzheimer's Disease in Miami Florida, September 16 2006. Sponsored by CMEducation Resources and the University of Massachusetts Medical School (UMMS)
- 70) Alva, G - Invited Speaker, "Identifying Ethnic and Cultural Diversity in Bipolar Disorder: Pathways to Improving the Care of Patients", U.S. Psychiatric & Mental Health Congress, November 17, 2006, New Orleans (CME Symposium)
- 71) Alva, G - Faculty at the 2008 American Medical Directors Association Annual Meeting in Salt Lake City, Utah "Deciphering Dementia with Concomitant Depression in Long Term Care"
- 72) Alva, G - Faculty at the Alzheimer's Disease International Conference, Singapore, 2009 "Exelon Patch Satellite Symposium"
- 73) Alva, G - Invited Speaker, Alzheimer's Association Orange County Chapter. Guiando con  
Respeto", February, 2010
- 74) Alva, G - Invited Speaker, CME Workshop for Physicians (Sponsored by Cal Optima and the Alzheimer's Association. "An Update on Alzheimer's Disease - California Guideline for Alzheimer's Disease Management", March 31, 2011

- 75) Alva, G and Maletic V - Invited Speakers, CME Presentation at the US Psychiatric and Mental Health Congress Meeting, November 8, 2012
- 76) Alva, G - Invited Speaker, PriMed Congress Meeting, May 2, 2013
- 77) Alva, G - Invited Speaker, APA Annual Meeting, May 19th, 2013
- 78) Alva, G - Invited Speaker, PriMed Congress Meeting, June 10, 2013
- 79) Alva, G-Invited Speaker, PriMed Congress Meeting, September 20, 2013
- 80) Alva, G-Invited Speaker, US Psychiatric Congress, "Potential Misconceptions About Long-Acting Injectable Use in Schizophrenia: Review of the Clinical Data for Abilify Maintena(tm) (aripiprazole), October 2, 2013
- 81) Alva, G – Invited Speaker, Current Psychiatry/American Academy of Clinical Psychiatry (AAC) Psychiatry Update 2014, Product Theater Presentation, Insights into a Major Depressive Disorder Treatment, Dec 11, 2014
- 82) Alva, G – Invited Speaker, Orange county Psychiatric Society, "Lurasidone, Votioxetine, Vilazodone, Levomilnacipran and Suvoroxone: When, Why and How to Use them", April 14, 2015
- 83)Alva, G – Invited Speaker, UCR Neuroscience Grand Rounds, "Progress in Defining Dementias and the Neuropathology and Treatment of AD", September 24, 2015

### **Abstracts and Posters**

**Alva, G,** et al. World Congress of Genetic Psychopharmacology, Bonn, Germany, 1998; Poster Presentation; **"A genetic PET scan study: D1 alleles predict clinical response to clozapine and corresponding brain metabolism**

Potkin SG, Bera R, Keator D, Fleming K, **Alva G**, Carreon D, Kranz L: **"Distinguishing Predominantly Negative Symptom Schizophrenia with FDG PET."** Poster presented at the International Congress on Schizophrenia Research, Santa Fe, NM, April 17-21, 1999

Potkin SG, Fleming K, Alphs L, **Alva G**, Anand R: "Neurocognition in Schizophrenic Patients at Risk for Suicide." Poster presented at the International Congress on Schizophrenia Research, Santa Fe, NM, April 17-21, 1999

Potkin SG, Basile VS, Badri F, Keator D, Wu JC, **Alva G**, Doo M, Bunney WE Jr., Kennedy JL: **"D1 Receptor Alleles Predict PET Metabolic Correlates of Clinical Response to Clozapine."** Abstract published in The International Journal of Neuropsychopharmacology, 3 (Suppl 1):S6, 2000

Fleming K, Jin Y, **Gustavo A**, Potkin S: **"The Neurocognitive Improvement of AIT-082 in Alzheimer's Disease,"** poster presented at ACNP 30<sup>th</sup> Annual Meeting, San Juan, Puerto Rico, poster presented at ACNP 30<sup>th</sup> Annual Meeting, San Juan, Puerto Rico, December 11, 2000

Potkin SG, Shipley J, Bera RB, Carreon D, Fallon JH, **Alva G**, Keator D, **"Clinical and PET Effects of M100907, A Selective 5HT-2A Receptor Antagonist"**, abstract published in Schizophrenia Research, 49 (1-2 Supplement):242

Kemp AS, Fleming K, Cohen E, Jin Y, Highum DM, **Alva G**, Bunney WE, Potkin SG, **"A Neurocognitive Evaluation of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex of Patients with Prominent Negative Symptom Schizophrenia"** poster presented at the International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28-May 2, 2001 and abstract published in Schizophrenia Research, 49 (1-2 Supplement):111

**Alva G**, Cohen E, Jin Y, Highum DM, Fleming K, Bunney WE, Potkin SG, **"Differential Effects of High and Low Frequency RTMS in Schizophrenia"**, poster presented 28-May 2, 2001 and abstract published in Schizophrenia Research, 49 (1-2 Supplement):219

Jin Y, Potkin SG, **Alva G**, Carreon D, Bunney WE, **"Reduced Peak Frequency and Selectivity of EEG Resonant Responses to Photic Stimulation in Schizophrenia"**, poster presented 28-May 2, 2001 and abstract published in Schizophrenia Research, 49 (1-2 Supplement):203

Potkin SG, **Alva G**, Panagides J, Carreon DT, Langstrom B, Mukherjee J, De Greef R, Bunney WE. **Predicting clinical antipsychotic doses from preclinical and PET studies: A case study with Asenapine.** ACNP 42<sup>nd</sup> Annual Meeting, San Juan, Puerto Rico; 12/2003

Potkin SG, Anand R, **Alva G**, Fleming K, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH: **FDG PET and Clinical Effects in Placebo and Rivastigmine Treated Subjects with Alzheimer's Disease**, International Congress of Geriatric Psychiatry, December 14-15, Waikoloa, Hawaii

**Alva G**, Farlow MR, Porsteinsson A, Graham SM, Jonas JM. **Update of Memantine Safety in Short and Long-term Treatment of Dementia.** International Psychogeriatric Association 2005 Meeting (September 20-24) in Stockholm, Sweden

**Alva G**, Farlow MR, Porsteinsson A, Graham SM, Lee G, Jonas JM, Stoffler A. **Update of Memantine Safety in Short and Long-term Treatment of Dementia.** American Psychiatric Association 158th Annual Meeting, Atlanta GA, 2005

**Alva G**, Agronin ME, Perkins D. **Prolactin Elevation Issues Associated with Atypical Antipsychotics**; Part 2 of a 2-part Series; CNS News, 2005 (Supplement)

**Alva G**, Blanco C. **Anxiety Disorders and Depression: 2 Cases of Comorbidity.** CNS Updates, 2005 (Supplement)

**Alva G**, Borson, S, Fillit H, Galvin JE, Sloane PD, Tangalos EG. **Diagnosing and Managing Alzheimer's Disease in the Family Practice Setting**; (Supplement to: Family Practice Recertification, April 2006, Vol. 28, No. 4

Tangalos EG, **Alva G**, Beier M, Borson S. **Facilitating Diagnosis and Management of Alzheimer's Disease in the Primary Care Setting**; (Monograph, University of Wisconsin and Precept Educational Sciences), 2006

**Alva G**, Grossberg G, Schmitt F, Olin JT. **Influence of rivastigmine patch on activities of daily living: Item responder analyses targeting improvement and stability.** Presented at the NCDEU annual meeting, 2009

**Alva G**, et al, **An Open Label Extension study Evaluating the Safety and Tolerability of Extended-release Memantine (once daily, 28 mg) in Patients with Moderate to Severe Alzheimer's Disease**, Poster presented at the American Association for Geriatric Psychiatry annual meeting in Bethesda, MD, 2010

**Alva G**, et al, **Safety and Tolerability of Extended-Release Memantine in Patients with Moderate to Severe Alzheimer's Disease: An Open-Label Extension Study**, Poster presented at the Annual Meeting of the American Neurological Association, San Francisco, 2010

**Alva G**, et al, **Safety and Tolerability of Extended-Release Memantine in Patients with Moderate to Severe Alzheimer's Disease: An Open-Label Extension Study**, Poster presented at the Annual Meeting of the American Association for Geriatric Psychiatry, Savannah, GA, 2010

**Alva G**, et al, **Safety and Tolerability of Extended-Release Memantine (once daily, 28 mg) in Patients with Moderate to Severe Alzheimer's Disease: An Open-Label Extension Study**,

Poster presentation at the American Neurological Association Annual Meeting in San Francisco, 2010

**Alva G, et al, Clinical Outcomes Following Two Methods of Switching to Iloperidone from Risperidone, Olanzapine, or Aripiprazole in Patients with Schizophrenia**, Poster presentation at the American Psychiatric Association 64th Institute on Psychiatric Services, New York City, October 2012

**Alva G, et al, Switching from Risperidone to Iloperidone in patients with Schizophrenia: Does an Efficacy or EPS Reason for switch affect clinical Outcomes and Tolerability?**, Poster presentation at the US Psychiatric and Mental/Health Congress annual Meeting, San Diego, Ca, 2012

**Alva G, Cummings, J, Winblad B, Grossberg G, Frolich L, Krahnke T, Downs P, Strohmaier C, High -dose 13.3 mg/24 hr Rivastigmine Transdermal patch demonstrates efficacy on instrumental activities of daily living: analysis of autonomy and higher-level function subscales.** 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden, 2012

**Alva G, Isaacson R, Somogyi M, Meng X, Efficacy of Higher-Dose 13.3 mg/24 H Rivastigmine Patch on the Alzheimer's Disease Assessment Scale-Cognitive Subscale: Individual Item Analyses**, Poster Presentation at the American Psychiatric Association Annual Meeting, San Francisco, Ca. 2013

**Alva G, Cummings J, Galvin J, Meng X, Somogyi M. Infrequent skin reactions at the application site of rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): analysis of two clinical studies reveals most are tolerable and manageable across all doses.** Poster Presentation at the Alzheimers Association International Conference Annual Meeting, Boston, Mas. 2013

Caputo A, Graf A, Riviere M-E, **Alva, G**, Balaguer E, Zacharias A, Maguire RP, Sovago J, Ryan JM, “**Active AB Immunotherapy CAD106 Phase II Dose-Adjuvant Finding Study: Amyloid PET.**” Poster presentation at

**Alva G, Citrome L, Weiden PJ, Glick ID, Winseck A, Kianifard F, Meng X. Initial 2-Week Outcomes Following 2 Methods of Switching to Iloperidone From Olanzapine in Patients With Schizophrenia.** Poster presentation at the NEI annual meeting, Colorado Springs, 2013

Winseck A, Glick ID, Weiden PJ, Citrome L, **Alva G**, Kianifard F, Meng X. **Initial 2-Week Outcomes Following 2 Methods of Switching to Iloperidone From Aripiprazole in Patients With Schizophrenia.** Poster presentation at the NEI annual meeting, Colorado Springs, 2013

Weiden PJ, Citrome L, Glick ID, **Alva G**, Winseck A, Kianifard F, Meng X. **Initial 2-Week Outcomes Following 2 Methods of Switching to Iloperidone From Risperidone in Patients With Schizophrenia.** Poster presentation at the NEI annual meeting, Colorado Springs, 2013

**Alva G, Cummings J, Galvin J, Meng X, Somogyi M. “Skin reactions at the application site of rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): a qualitative analysis of two clinical studies”** Poster presentation at the 2013 American Society of Consultant Pharmacists Annual Meeting & Exhibition, Seattle, WA, USA, November 20–22, 2013

Grossberg, GT, **Alva G**, Hendrix S, Hofbauer RK, Pejovic V, Graham SM. “**Efficacy and Tolerability of Memantine Extended Release Added to Stable Donepezil Regimen in Individuals with Moderate to Severe Alzheimer's Disease: Subset Analysis of a Randomized Clinical Trial**”, Poster presentation at the 2014 Alzheimer's Association International Conference, July 12-17, 2014

**Alva G**, Hendrix S, Ellison N, Pejovic V, Otcheretko V. **“Adding Memantine to Stable Cholinesterase Inhibitor Therapy in Patients with Moderate to Severe Alzheimer’s Disease is Associated with Improvement in Various Neuropsychiatric Symptoms: A Pooled Analysis”**., Poster presentation at the 2015 American Academy of Neurology’s Annual Meeting, April 18-25, Washington DC

**Alva G.**, Ellison N., Dass B., Hendrix, S. **“Daily Functioning Benefits of Adding Memantine to Stable Cholinesterase Treatment in Patients with Moderate to Severe Alzheimer’s Disease: A Post Hoc Pooled Factor Analysis”**, Poster presentation at the 2015 CtaD Meeting November 5-7, in Barcelona, Spain

### **Service to professional societies**

**American Psychiatric Association, General Member**  
**California Psychiatric Association, Bill Reviewer for Government Affairs Committee**  
**Orange County Psychiatric Society, Executive Council Member**  
**California Hispanic American Medical Association, General Member**  
**American Medical Association, General Member**  
**Orange County Medical Association, General Member, Government Affairs Committee**  
**American College of Forensic Examiners, General Member**

### **Membership in professional organizations**

American Medical Association  
Orange County Medical Association  
Legislative Committee, OCMA  
California Psychiatric Association  
Orange County Psychiatric Society  
Executive Council Member, OCPS  
Government Affairs Committee, OCPS  
Public Affairs Committee, OCPS  
Speaker, OCPS Expert Speakers Bureau  
American Board of Forensic Medicine  
American College of Forensic Examiners  
California Hispanic American Medical Association  
Hispanic-American Biomedical Association

1996-1997 Deputy Resident Representative, CPA  
1997-1998 Resident Representative, OCPS, Area 6 Resident Representative, APA  
1996-1998 Assembly, APA Assembly Liaison for the Council of Psychiatry and the law, APA  
1997-1999 Board Member, Orange County Mental Health Board  
1998-2000 Early-Career-Psychiatrist-Representative, OCPS

### **UNIVERSITY AND PUBLIC SERVICE**

#### **System Wide**

Institutional Review Board, July 1999-2006

Pharmacy and Therapeutics Committee July 1999-2003

#### **Campus - UCI Academic Senate and Administrative Service**

Admissions Committee for the College of Medicine, 2000 - 2006

#### **School - College of Medicine**

Admissions Committee for the College of Medicine, 2000 – 2006

Clinical Instructor, Psychiatry course for medical students, UCI College of Medicine, 2000-2006

#### **Department of Psychiatry And Human Behavior**

Quality Assurance/Utilization Review Committee, July 1999-2006

Administrative/Interdisciplinary Council, July 1999-2006

Medicare Compliance Committee, July 1999-2006

2012-Present - Clinical Instructor, Psychiatry course for first year residents, UCI Psychiatry Residency Program

#### **Community**

Advisory Boards:

2012-Present Medical/Scientific Advisory Board, Mush Foundation

2000-Present Medical/Scientific Advisory Board, Alzheimer's Association of Orange County

2000-2004 YMCA Board of Managers

2000-Present Orange County council on Aging

2000-2006 Psychiatric Health Steering Committee for Congresswoman Loretta Sanchez

Board Member, YMCA Board of Managers

Speaker for the Manic Depressive Association of Orange County

Speaker for the Orange County Alliance for the Mentally Ill

2010, Orange Coast Magazine Top Psychiatrist of Orange County

2011, Orange Coast Magazine Top Psychiatrist of Orange County

2013, Orange Coast Magazine Top Psychiatrist of Orange County

#### **PUBLICATIONS**

##### **Journal Articles Peer Reviewed**

Article: Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, **Alva G**, Kalow W, Macciardi FM, Kennedy JL. **A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.** Mol Psychiatry. 2000 Jul;5(4):410-7.

Article: Potkin SG, Anand R, Fleming K, **Alva G**, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH. **Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.** Int J Neuropsychopharmacol. 2001 Sep;4(3):223-30.

Article: Potkin SG, **Alva G**, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH. **A PET study of the pathophysiology of negative symptoms in schizophrenia.** Am J Psychiatry. 2002 Feb;159(2):227-37.

Article: Potkin SG, Thyrum PT, **Alva G**, Bera R, Yeh C, Arvanitis LA. **The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.** J Clin Psychopharmacol. 2002 Apr;22(2):121-30.

Article: Potkin SG, Thyrum PT, **Alva G**, Carreon D, Yeh C, Kalali A, Arvanitis LA; Pharmacokinetic Study Group. **Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.** J Clin Psychopharmacol. 2002 Apr;22(2):174-82.

Article: Potkin SG, **Alva G**, Keator D, Carreon D, Fleming K, Fallon JH. **Brain metabolic effects of Neotrofin in patients with Alzheimer's disease.** Brain Res. 2002 Sep 27;951(1):87-95.

Article: Potkin SG, Thyrum PT, Bera R, Carreon D, **Alva G**, Kalali AH, Yeh C. **Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and**

**tolerability.** Clin Ther. 2002 Nov;24(11):1809-23.

Article: **Alva, G: The Challenge of Dementia: Preserving Cognition and Behavior.** Cognitive and Behavioral aspect of neuropsychiatric disorders, 2002

Article: Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, **Alva G**, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL. Conference Proceedings Papers, Peer Reviewed. **D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine.** Mol Psychiatry. 2003 Jan;8(1):109-13.

Article: **Alva G**, Potkin SG. **Alzheimer disease and other dementias.** Clin Geriatr Med. 2003 Nov;19(4):763-76. Review.

Article: Jin Y, Potkin SG, Huerta S, **Alva G**, Kang P, Bunney WE. **EEG-guided RTMS improves negative symptoms in schizophrenia.** Schizophrenia Research 03/2003; 60(1):287-288

Article: **Alva, G.: Treating psychotic symptoms in Alzheimer's disease with atypical antipsychotics.** Case-Based Medicine Teaching Series, 2004

Article: Potkin SG, McDonald S, Gergel I, **Alva G**, Keator DB, Fallon JH. **Memantine monotherapy increases brain metabolism (PET) and effectively treats mild to moderate Alzheimer's disease.** European Neuropsychopharmacology. 10/2004; 14

Article: Potkin SG, McDonald S, Gergel I, **Alva G**, Keator DB, Fallon JH. **Memantine monotherapy increases brain metabolism (PET) and effectively treats mild to moderate Alzheimer's disease.** Neurobiology of Aging 07/2004; 25

Article: Fleming K, Turner J, **Alva G**, Potkin SG. **P2-373 Relative Sparing of picture learning in Alzheimer's disease.** Neurobiology of Aging. 07/2004; 25

Article: Potkin SG, **Alva G**, Gunay I, Koumaras B, Chen M, Mirski D. **A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.** Drugs Aging. 2006;23(3):241-9

Article: Jin Y, Potkin SG, Kemp AS, Huerta S, **Alva G**, Thai MT, Carreon D, Bunney WE. **Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the Negative symptoms of schizophrenia.** Schizophrenia Bulletin. 2006; 32 (3):556-61.

Article: DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, **Alva G.** **Mifepristone vs. Placebo in the Treatment of Psychosis in Patients with Psychotic Major Depression.** Biological Psychiatry. 01/2007; 60(12):1343-9

Article: **Alva, G., Cummings J., Relative Tolerability of Alzheimer's Disease Treatments.** Psychiatry 2008. 2008 Nov;5(11):27-36

Article: Farlow MR, Graham SM, **Alva G.** **Memantine for the Treatment of Alzheimer's Disease.** Drug Safety 01/2008; 31 (7).

Article: Farlow M, Darreh-Shori T, Peskind E, **Alva G**, Eagle G, Nordberg A. **The effect of Cholinesterase inhibitors on the levels and activities of cholinesterases in the cerebrospinal fluid of Alzheimer's disease patients.** Neurology 3/2008; 70(11):A99-A99

Article: **Alva G**, Farlow M, Sadowsky C, Brennan S. **SWAP: the safety and tolerability of**

**switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease**  
Aktuelle Neurologie 9/2009; 36(S 02).

Article: Farlow MR, **Alva G**, Meng X, Olin JT. **A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.** Current Medical Research and Opinion, 11/2009; 26(2):263-9

Article: **Alva G**, Grossberg G, Schmitt AF, Meng X, Olin JT  
**Efficacy of rivastigmine transdermal patch on activities of daily living: Item responder analyses.** International Journal of Geriatric Psychiatry 2011;26(4); 356–363

Article: **Alva G**, Cummings J, Galvin J, Meng X, Somogyi M. **Infrequent skin reactions at the application site of the Rivastigmine Patch (4.6, 9.5 or 13.3 mg/24/h): Analysis of two clinical studies revealed most were tolerable and manageable across all doses.** Alzheimer's and Dementia 7/2013; 9(4):P666

Article: Shankle, WR, Hara, J, Mangrola, T, Hendrix, S, **Alva, G**, Lee, MD. **“Hierarchical Bayesian cognitive processing models to analyze clinical trial data”**, Alzheimer's & Dementia Volume 9, Issue 4, July 2013, Pages 422–428

Article: Weiden PJ, Citrome L, **Alva G**, Brams M, Glick ID, Jackson R, Mattingly G, Kianifard F, Meng X, Pestreich L, Hochfeld M, Winseck A: **A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.** Schizophr Res; 2014 Mar;153(1-3):160-8

Article: **Alva G**, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M. **Efficacy of higher-dose 13.3 mg/24 h (15 cm<sup>2</sup>) rivastigmine patch on the Alzheimer's Disease Assessment Scale–cognitive subscale: domain and individual item analysis**  
Vol 29, Issue 9. International Journal of Geriatric Psychiatry 2014: August 8, 2014 Page 920-

Article: Kerbage C, Sadowsky CH, Tariot PN, Agronin M, **Alva G**, Turner FD, Nilan D, Cameron A, Cagle GD, Hartung PD. **Detection of Amyloid Beta Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer' Disease.** American Journal of Alzheimer's Disease and Other Dementias, 2/2014.

Article: **Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.** International Journal of Clinical Practice 02/2015; 69(5)

Article: **Switching to Iloperidone: An Omnibus of Clinically Relevant Observations from a 12-Week, Open-Label, Randomized Clinical Trial in 500 Persons with Schizophrenia**  
Leslie Citrome, Peter J. Weiden, Gus Alva, et al; Volume 8, Number 4/January 2015 of Clinical Schizophrenia & Related Psychoses

#### **Supplements and Presentations:**

Potkin SG, Fleming K, Alphs L, **Alva G**, Anand R: “Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. **A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.** Mol Psychiatry. 2000 Jul;5(4):410-7.



Potkin SG, Basile VS, Badri F, Keator D, Wu JC, **Alva G**, Doo M, Bunney WE Jr., Kennedy JL: **"D1 Receptor Alleles Predict PET Metabolic Correlates of Clinical Response to Clozapine."** Abstract published in The International Journal of Neuropsychopharmacology, 3(Suppl 1):S6, 2000.

Potkin SG, Shipley J, Bera RB, Carreon D, Fallon J, **Alva G**, Keator D, **"Clinical and PET Effects of M100907, A Selective 5HT-2A Receptor Antagonist"**, abstract published in Schizophrenia Research, 49(1-2 Supplement):242.

Kemp AS, Fleming K, Cohen E, Jin Y, Highum DM, **Alva G**, Bunney WE, Potkin SG, **"A Neurocognitive Evaluation of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex of Patients with Prominent Negative Symptom Schizophrenia"** poster presented at the International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28 – May 2, 2001 and abstract published in Schizophrenia Research, 49(1-2 Supplement):111.

**Alva G**, Cohen E, Jin Y, Highum DM, Fleming K, Bunney WE, Potkin SG, **"Differential Effects of High and Low Frequency RTMS in Schizophrenia"**, poster presented at the International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28-May 2, 2001 and abstract published in Schizophrenia Research, 49(1-2 Supplement):219.

Jin Y, Potkin SG, **Alva G**, Carreon D, Bunney WE, **"Reduced Peak Frequency and Selectivity of EEG Resonant Responses to Photic Stimulation in Schizophrenia"**, poster presented at the International Congress on Schizophrenia Research, Whistler, British Columbia, Canada, April 28 – May 2, 2001 and abstract published in Schizophrenia Research, 49(1-2 Supplement):203.

Burke, W, **Alva, G. Anxiety Disorders and Depression: Two Cases of Comorbidity** (Supplement)

**Alva, G** and Beier, Manju. CNS News and CNS Long-Term Care; **"Modifying Alzheimer's Disease Progression in Long-Term Care: An Interactive Discussion** (A CME/CE newsletter based on the content of a satellite symposium at the American Medical Directors Association 28<sup>th</sup> Annual Symposium held on March 17, 2005

**Alva, G**, Siegal, A, Cadeiux, R, et al., **Challenges in the treatment of Anxiety and Depression in the elderly patient**, CNS News, July 2006 (Continuing Medical Education)

### **Articles in Medical Magazines and Newspapers**

1. Profiles in Practice #3 in a series What's your Diagnosis? (Sponsored by Forest Pharmaceuticals) ; **Diagnosing Alzheimer's Disease**, Review by **Alva G**

1. Target Topic: Alzheimer's; A Publication Series Dedicated to Supporting Physician Awareness, **"I think I have a memory problem..."**, Editorial Consultants: **Alva G**, Doody RS, Daillo LA, Pfeiffer E, Tariot PN

1. Target Topic: Alzheimer's; A Publication Series Dedicated to Supporting Physician Awareness, **"We have a diagnosis and it's time to begin treatment..."**, Editorial Consultants: **Alva G**, Doody RS, Daillo LA, Pfeiffer E, Tariot PN

1. Target Topic: Alzheimer's; A Publication Series Dedicated to Supporting Physician Awareness, **"It's time to discuss managing treatment at home..."**, Editorial Consultants:

**Alva G**, Doody RS, Dailello LA, Pfeiffer E, Tariot PN.

### **Articles in General Readership Magazines and Newspapers**

1. Update on Alzheimer's Dementia; Elderly Health Magazine of Orange County
2. OC Metro, Sept., 2004 "Stressed Out" (Cover story) by Nguyet Le Thomas, citations

### **Videotapes**

1. Update on Alzheimer's Disease; Adelphia Cable with Fina Bentley

### **Web based Programs**

1. Video Jug; Educational programs on Neuropsychiatric themes
2. Featured on Caregiver Action Network's website here:  
<http://www.caregiveraction.org/resources/alzheimer-videos/>

### **Television Programs**

1. Featured in "Salud es Vida" on Univision speaking on Alzheimer's Disease and therapies on four separate occasions in 2012
2. Featured as an invited guest on "Despierta America" on Univision, on 10 occasions as a live guest in 2012 to educate on differences between age related memory decline and early signs of dementia

### **PERSONAL**

Highly interested in psychiatric research and education pertaining to Alzheimer's Dementia, Schizophrenia, Bipolar Disorder, Major Depressive Disorder and Anxiety Disorders. Focusing on the genetics, neuroimaging and latest treatments available for each condition as well as ethnicity and its correlation with the aforementioned clinical situations.